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Anna Maria Gori, MD, Rosanna Abbate, MD, David Antoniucci, MD
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Objectives We sought to determine whether nonresponsiveness to clopidogrel as revealed by high in vitro post-treatment
platelet reactivity is predictive of drug-eluting stent (DES) thrombosis.
Background No data exist about the impact of nonresponsiveness to clopidogrel on the risk of DES thrombosis.
Methods We conducted a prospective observational cohort study from July 2005 to August 2006 in an academic hospital.
A total of 804 patients who had successful sirolimus- or paclitaxel-eluting stent implantation were assessed for
post-treatment platelet reactivity after a loading dose of 600 mg of clopidogrel. Patients with platelet aggrega-
tion by 10 mol adenosine 5=-diphosphate 70% were defined as nonresponders. All patients received chronic
dual antiplatelet treatment (aspirin 325 mg and clopidogrel 75 mg daily) for 6 months. The primary end point
was the incidence of definite/probable early, subacute, and late stent thrombosis at 6-month follow-up.
Results The incidence of 6-month definite/probable stent thrombosis was 3.1%. All stent thromboses were subacute or
late. Of 804 patients, 105 (13%) were not responsive to clopidogrel. The incidence of stent thrombosis was
8.6% in nonresponders and 2.3% in responders (p  0.001). By multivariate analysis, the predictors of stent
thrombosis were as follows: nonresponsiveness to clopidogrel (hazard ratio [HR] 3.08, 95% confidence interval
[CI] 1.32 to 7.16; p  0.009), left ventricular ejection fraction (HR 0.95, 95% CI 0.92 to 0.98; p  0.001), total
stent length (HR 1.01, 95% CI 1.00 to 1.02; p  0.010), and ST-segment elevation acute myocardial infarction
(HR 2.41, 95% CI 1.04 to 5.63; p  0.041).
Conclusions Nonresponsiveness to clopidogrel is a strong independent predictor of stent thrombosis in patients receiving
sirolimus- or paclitaxel-eluting stents. (J Am Coll Cardiol 2007;49:2312–7) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.01.094r
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A dual antiplatelet regimen of aspirin and
clopidogrel is the standard treatment for the
prevention of stent thrombosis (1–3), and ret-
rospective studies have shown that the discon-
tinuation of clopidogrel, even after 6 months or
later after stent implantation, is associated with
n increased risk of thrombotic events in patients with
rug-eluting stents (DES) (4–7). However, stent thrombo-
is also can occur in patients taking clopidogrel and aspirin,
nd it has been shown that patients who suffer stent
hrombosis have a high in vitro post-treatment platelet
eactivity despite the dual antiplatelet treatment, suggesting
hat platelet aggregation nonresponsiveness to clopidogrel is
he main cause of the thrombotic event (8–12). The definite
emonstration of the association between low in vitro
rom the Department of Cardiology, Careggi Hospital, Florence, Italy.r
Manuscript received January 2, 2007; revised manuscript received January 26, 2007,
ccepted January 28, 2007.esponsiveness to clopidogrel and thrombotic events is still
acking because the large majority of previous studies were
etrospective or underpowered. Moreover, post-treatment
latelet reactivity may interact with 1 or more established
linical and procedural predictors of stent thrombosis, mak-
ng it difficult to define its role in precipitating thrombosis.
n addition, studies have used different platelet reactivity
ssessments and definitions for determining the platelet
esponsiveness to clopidogrel. This prospective study sought
o determine the impact of low responsiveness to clopi-
ogrel on the clinical outcome of patients receiving DES.
See page 2318
ethods
atients. This study is based on a cohort of 804 consecu-
ive patients who received successful sirolimus- or
aclitaxel-eluting stent implantation and for whom platelet
eactivity after clopidogrel treatment was prospectively as-
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June 19, 2007:2312–7 DES and Nonresponsiveness to Clopidogrelessed. All patients were considered eligible for the study
rrespective of clinical presentation or coronary anatomy.
hus, patients with acute coronary syndromes and ST-
egment elevation acute myocardial infarction (AMI) were
ncluded, as well as patients with left main disease, chronic
otal occlusions, bifurcation lesions, or diffuse disease. The
nly exclusion criteria were: 1) in-hospital death that was
ot due to stent thrombosis; 2) anticipated noncompliance
o dual antiplatelet treatment for at least 6 months; and
) premature discontinuation of clopidogrel therapy. All
atients gave informed consent. The study was approved by
he local ethical committee.
ercutaneous coronary intervention and antiplatelet
anagement. All interventions were performed according
o current standard guidelines, and the type of stent im-
lanted and the use of IIb/IIIa inhibitors were at discretion
f the operator. All patients received aspirin (325 mg) and
loading dose of 600 mg of clopidogrel followed by a
aintenance dose of 75 mg daily. Patients on a maintenance
ose of ticlopidine or clopidogrel at the time of admission
eceived a loading dose of clopidogrel (600 mg).
latelet reactivity assessment. Blood samples anticoagu-
ated with 0.129 mol/l sodium citrate (ratio 9:1) for platelet
eactivity assessment was obtained 12 to 18 h from clopi-
ogrel loading. For patients receiving in the cath lab both
he loading dose of clopidogrel and a IIb/IIIa inhibitor,
lood samples were obtained after 6 days while the patient
as on the 75-mg maintenance dose of clopidogrel.
latelet-rich plasma, obtained by centrifuging whole blood
or 10 min at 200 g, was stimulated with 10 mol/l
denosine 5=-diphosphate (ADP) (Mascia Brunelli, Milan,
taly) and residual aggregation was assessed using a APACT
light transmittance aggregometer (Helena Laboratories,
ilan, Italy). The 100% line was set using platelet-poor
lasma and the 0 baseline established with platelet-rich
lasma (adjusted from 18 109/l up to 30 109/l). Platelet
ggregation (according to the Born’s method) was evaluated
onsidering the maximal percentage of platelet aggregation
n response to stimulus. Control samples from 100 healthy
olunteers were run to determine the normal reference
aboratory aggregation value that was 68% (range 55% to
9%). Patients with platelet aggregation by 10-mol ADP
90th percentile of controls (70%) were defined as
onresponders.
nd points. The primary end point of the study was
efinite or probable stent thrombosis during a 6-month
ollow-up. Definite stent thrombosis was defined as acute
oronary syndrome and either angiographic confirmation of
hrombosis or pathological confirmation of thrombosis.
robable stent thrombosis was defined as unexplained death
r myocardial infarction in the territory supplied by a
tented vessel without angiographic confirmation. The di-
gnosis of myocardial infarction was based on either the
evelopment of new Q waves on 2 or more electrocardio-
raphic leads or an increase of creatine kinase-myocardial
and isoenzyme or troponin T 3 times the upper limit of aormal. Event time was catego-
ized as acute (within 24 h from
tent implantation), subacute
from 1 day to 30 days), and late
30 days to 6 months). The sec-
ndary end point was the com-
osite of cardiac mortality and
efinite or probable stent throm-
osis. All events were adjudi-
ated by 3 observers (A.M.,
.A., G.M.) who were blinded
o patient responsiveness to clo-
idogrel and not involved in the
ollow-up process.
ollow-up. All patients had scheduled clinical and electro-
adiographic examinations at 1, 3, and 6 months. All other
ossible information derived from hospital readmission or
y the referring physician, relatives, or municipality live
egistries was entered into the database.
tatistical analysis. The sample size was calculated assum-
ng the incidence of the primary end point to be 2%, and we
ypothesized a 3.5-fold increase in the incidence of stent
hrombosis in nonresponders to clopidogrel. With these
ssumptions, to have a power of 0.80 to detect the hypote-
ized effect size with a 1-sided p value 0.05, a sample size
f at least 800 was needed. Discrete data are summarized as
requencies, whereas continuous data as mean  SD. The
hi-square test was used for comparison of categorical
ariables. A 2-tailed Student t test was used to test differ-
nces among continuous variables. Forward stepwise Cox
roportional hazards regression analysis was performed to
dentify independent correlates of the primary and second-
ry end point. The variables entered in the proportional
azards regression model were selected using stepwise
egression analysis with an entry criterion of p  0.10.
azard ratio (HR) and 95% confidence intervals (CIs) were
alculated. Survival curves were generated using the Kaplan-
eier method, and the difference between curves was
ssessed by log-rank test. A p value 0.05 was considered
ignificant. Analyses were performed using the software
ackage SPSS 8.0 (SPSS Inc., Chicago, Illinois).
esults
atient and procedural characteristics. The study cohort
omprised 804 patients who were treated from July 2005
o February 2006 with sirolimus- (Cypher, Cordis Corp.,
iami Lakes, Florida) or paclitaxel- (Taxus, Boston
cientific Corp., Natick, Massachusetts) eluting stents.
here were 105 patients who were not responsive to
lopidogrel (13%). Table 1 summarizes the clinical and
rocedural characteristics of the patients. Nonresponsive
atients were older as compared with responders; had a
reater incidence of diabetes mellitus, unstable angina, and
ultivessel disease; and had a lower incidence of smoking
Abbreviations
and Acronyms
ADP  adenosine
5=-diphosphate
AMI  acute myocardial
infarction
CI  confidence interval
DES  drug-eluting stent(s)
HR  hazard ratio
LVEF  left ventricular
ejection fractionnd ST-segment elevation myocardial infarction. Left ven-
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DES and Nonresponsiveness to Clopidogrel June 19, 2007:2312–7ricular ejection fraction (LVEF) was significantly lower in
he nonresponder group. Multivessel intervention was per-
ormed more frequently in nonresponders as compared with
esponders. Again, lesions at high risk of stent thrombosis,
uch as long lesions and the total chronic occlusions, were
Baseline Clinical and ProceduralCharacteristics According to Responsiveness to
Table 1 Baseline Clinical and ProceduralCharacteristics According to Respo
Overall
(n  804)
Variable 69  11
Male gender, n (%) 602 (75)
Current smokers, n (%) 179 (22)
Arterial hypertension, n (%) 501 (62)
Diabetes mellitus, n (%) 169 (21)
Hypercholesterolemia, n (%) 405 (50)
Previous myocardial infarction, n (%) 206 (26)
Previous PCI, n (%) 186 (23)
Previous coronary artery surgery, n (%) 58 (7)
Stable angina, n (%) 275 (34)
Unstable angina, n (%) 312 (39)
Acute myocardial infarction, n (%)* 217 (27)
Renal failure, n (%) 87 (11)
Multivessel disease, n (%) 457 (57)
2-vessel disease 226 (28)
3-vessel disease 231 (29)
LVEF (%) 47  12
Multivessel PCI, n (%) 327 (41)
Vessel treated, n 1,220
Lesion treated, n 1,369
Thrombus-containing lesion, n (%) 177 (13)
Bifurcation lesion, n (%) 371 (27)
Chronic total occlusion, n (%) 106 (8)
Lesion length 20 mm, n (%) 359 (26)
Total stent length (mm) 38  29
Sirolimus-eluting stent, n (%) 447 (56)
Paclitaxel-eluting stent, n (%) 303 (38)
Both stent types, n (%) 54 (7)
Post-PCI MLD (mm) 2.81 (0.54)
Glycoprotein IIb/IIIa, n (%) 349 (43)
*ST-segment elevation acute myocardial infarction.
LVEF  left ventricular ejection fraction; MLD  minimum lumen d
Clinical Outcome
Table 2 Clinical Outcome
Definite/probable stent thrombosis, n (%)
Definite
Probable
Timing of stent thrombosis, n (%)
Early
Subacute
Late
Cardiac mortality, n (%)
Composite of cardiac death and stent thrombosis, n (%)
ST-segment elevation AMI, n
Stent thrombosis, n (%)AMI  acute myocardial infarction.reated more frequently in nonresponder patient group. As a
onsequence, the mean stent length per patient of the nonre-
ponder group was superior to the one of the responder group.
linical outcome. The follow-up rate was 100%. Table 2
hows the clinical outcome at 6 months. The overall primary
idogrel
ness to Clopidogrel
Responders
(n  699)
Nonresponders
(n  105) p Value
68  11 71  10 0.021
528 (76) 74 (70) 0.265
164 (24) 15 (14) 0.034
434 (62) 67 (64) 0.748
131 (19) 38 (36) 0.001
347 (50) 58 (55) 0.291
173 (25) 33 (31) 0.146
160 (23) 26 (25) 0.841
50 (7) 8 (8) 0.866
242 (35) 33 (31) 0.520
258 (37) 54 (51) 0.004
199 (28) 18 (17) 0.015
73 (10) 14 (14) 0.374
386 (55) 71 (68) 0.017
190 (27) 36 (34)
196 (28) 35 (33)
47  12 44  14 0.008
273 (39) 54 (51) 0.016
1,044 176
1,171 198
166 (24) 11 (10) .001
318 (27) 53 (27) 0.909
86 (7) 20 (10) 0.180
294 (25) 65 (33) 0.022
37  29 44  32 0.015
391 (56) 56 (53) 0.617
264 (38) 39 (37) 0.902
44 (6) 10 (10) 0.218
2.81 (0.54) 2.80 (0.54) 0.832
311 (44) 38 (36) 0.110
r; PCI  percutaneous coronary intervention.
erall
804)
Responders
(n  699)
Nonresponders
(n  105) p Value
(3.1) 16 (2.3) 9 (8.6) 0.001
(1.4) 9 (1.3) 2 (1.9) 0.612
(1.7) 7 (1.0) 7 (6.7) 0.001
0 0 0
(2.0) 12 (1.7) 4 (3.8) 0.152
(1.1) 4 (0.6) 5 (4.8) 0.001
(2.4) 10 (1.4) 9 (8.6) 0.001
(3.5) 19 (2.7) 11 (10.5) 0.001
17 199 18
(5.1) 7 (3.5) 4 (22) 0.001Clop
nsiveOv
(n 
25
11
14
16
9
19
30
2
11
e
t
n
0
r
s
r
w
f
p
1
e
s
t
7
m
t
S
s
s
L
F
p
r
i
T
o
s
s
m
w
9
A
s
a
s
t
(
e
t
0
0
D
T
t
c
o
0
t
t
t
a
o
l
m

i
p
w
I
q
r
r
t
t
d
(
a
P
*
2315JACC Vol. 49, No. 24, 2007 Buonamici et al.
June 19, 2007:2312–7 DES and Nonresponsiveness to Clopidogrelnd point rate was 3.1%. Patients with ST-segment eleva-
ion AMI had a greater thrombosis rate as compared with
on-AMI patients (5.1% and 2.3%, respectively, p 
.052). There were no differences in the stent thrombosis
ate among patients receving sirolimus- or paclitaxel-eluting
tents or both types of stents (3.4%, 2.3%, and 5.6%,
espectively, p  0.406). Most of stent thromboses (64%)
ere subacute and occurred at a mean time of 54  62 days
rom stent implantation (range 4 to 180 days), whereas no
atient had acute stent thrombosis.
Definite or probable stent thrombosis occurred in 9 of
05 (8.6%) nonresponders and in 16 of 699 (2.3%) respond-
rs (p  0.001). In both groups, patients who developed
tent thrombosis had multiple high-risk features. Among
he 16 responder patients with stent thrombosis, there were
patients with AMI, 10 with bifurcation lesions, 10 with
ultivessel percutaneous coronary interventions, 8 with a
otal stent length 30 mm, and 8 with an LVEF 30%.
imilarly, among the 9 nonresponders with stent thrombo-
is, 3 had AMI, 5 multivessel intervention, 5 bifurcation
tenting, 8 had a total stent length 30 mm, and 5 had a
VEF 30%. The event-free survival curves are shown in
igure 1. The event-free survival rate from the primary end
oint was 91.3% in the nonresponders and 98.1% in the
esponders (p 0.001). The cardiac mortality rate was 8.6%
n the nonresponders and 1.4% in responders (p  0.001).
he incidence of the composite of cardiac death and definite
r probable stent thrombosis was 10.5% in the nonre-
ponders and 2.7% in the responders (p  0.001). Table 3
hows the results of univariate and multivariate analyses. By
ultivariate analysis, the predictors of the primary end point
ere as follows: nonresponsiveness to clopidogrel (HR 3.08,
5% CI 1.32 to 7.16; p  0.009), ST-segment elevation
MI (HR 2.41, 95% CI 1.04 to 5.63; p  0.041), total
tent length (HR 1.01, 95% CI 1.00 to 1.02; p  0.010),
nd LVEF (HR 0.95, 95% CI 0.92 to 0.98; p 0.001). The
ame variables also were independently related to the risk of
he secondary end point: nonresponsiveness to clopidogrel
Kaplan-Meier Analysis of Primary End Point forhResponders and Nonresponders to ClopidogrelHR 3.25, 95% CI 1.51 to 7.00; p  0.003), ST-segment
levation AMI (HR 3.25, 95% CI 1.46 to 7.23; p  0.004),
otal stent length (HR 1.01, 95% CI 1.00 to 1.02; p 
.006), and LVEF (HR 0.94, 95% CI 0.91 to 0.96; p 
.001).
iscussion
he definite or probable DES thrombosis rate of 3.1% in
his study was greater as compared with randomized trials
omparing DES with bare-metal stents and to previous
bservational studies that reported a thrombosis rate of
.8% to 1.5% (6,7,13–15). Baseline and procedural charac-
eristics of our patient cohort may explain the high stent
hrombosis rate: as compared with these studies, our pa-
ients were older and had a greater incidence of unstable
ngina or ST-segment elevation AMI, chronic coronary
cclusion, and bifurcation lesion.
This prospective study showed that post-treatment plate-
et aggregation after a 600-mg dose of clopidogrel is a strong
arker of the risk of DES thrombosis. Patients with in vitro
70% post-treatment platelet aggregation had nearly 4-fold
ncrease in definite or probable stent thrombosis as com-
ared with clopidogrel responders.
Platelet reactivity assessment to address clinical outcome
as based on the results of previous studies (10,16,17).
n vitro platelet reactivity after clopidogrel loading may be
uite variable, and low or nonresponsiveness may be the
esult of inadequate generation of the active drug metabolite
equired to inhibit the P2Y12 receptors. The mechanisms of
his variability may lie in the hepatic CYP3A4 pathway, in
he polymorphisms of CYP3A4 or P2Y12 receptor, or
ifferences in the rate of intestinal absorption of clopidogrel
18,19). Again, responsiveness, as assessed by in vitro tests,
lso depends on the baseline platelet reactivity, which is
redictors of Stent Thrombosis
Table 3 Predictors of Stent Thrombosis
Hazard Ratio
(95% Confidence Interval) p Value
Univariate analysis*
Nonresponsiveness to clopidogrel 3.85 (1.70–8.71) 0.001
Total chronic occlusion 2.98 (1.24–7.13) 0.014
Multivessel disease 2.43 (0.97–6.09) 0.058
Bifurcation lesion 2.27 (1.03–4.99) 0.042
Acute myocardial infarction 2.16 (0.98–4.57) 0.057
Previous myocardial infarction 1.97 (0.89–4.39) 0.096
Age, yrs 1.04 (1.00–1.08) 0.064
Total stent length, mm 1.02 (1.01–1.02) 0.001
LVEF per 1% increase 0.94 (0.91–0.96) 0.001
Multivariate analysis
Nonresponsiveness to clopidogrel 3.08 (1.32–7.16) 0.009
Acute myocardial infarction 2.41 (1.04–5.63) 0.041
Total stent length, mm 1.01 (1.00–1.02) 0.010
LVEF per 1% increase 0.95 (0.92–0.98) 0.001
Variables with a p value 0.10 that were entered in the multivariate model.
LVEF  left ventricular ejection fraction.Figure 1
igher in acute coronary syndromes as compared with stable
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DES and Nonresponsiveness to Clopidogrel June 19, 2007:2312–7oronary artery disease (20,21). Furthermore, clopidogrel
esponsiveness is also dose dependent, and it has been
hown that the incidence of low or nonresponders decreases
ramatically after a 600-mg loading dose of the drug as
ompared with the original 300-mg dose (22–26).
Despite these variables in the single patient that may
ffect his or her responsiveness to clopidogrel over time, our
tudy, based on a large unrestricted cohort of patients
eceiving drug-eluting stents, shows that a single assessment
f the in vitro responsiveness to clopidogrel is strongly
elated to the risk of drug-eluting stent thrombosis.
The clinical relevance of low or nonresponsiveness to
lopidogrel in patients receiving DES has not been fully
nvestigated. A prospective study based on a sample of 379
atients undergoing coronary stent implantation showed
hat low responsiveness to clopidogrel is associated with an
ncreased risk of adverse events (HR 3.71, 95% CI 1.08 to
2.69; p  0.037) at 3-month follow-up (27). This study
sed an arbitrary cutoff for the definition of low responsive-
ess (clopidogrel-dependent platelet inhibition 30%), had
very short follow-up, did not focus on DES thrombosis,
nd also included in the primary end point nonfatal isch-
mic stroke and any cardiovascular death.
Another study, based on a sample of 802 patients who
eceived elective coronary stent implantation, showed that
ost-treatment platelet aggregation above the median value
arried a 6.7-fold increase in major adverse cardiac events
death, myocardial infarction, and target vessel revascular-
zation) at 1-month follow-up (17). This study enrolled
ainly low-risk patients with stable coronary artery disease
ho received, in the large majority of cases, elective bare-
etal stent implantation. Again, this study focused more on
eriprocedural events, whose rate was very low (1.9%) and
ostly driven by target lesion revascularization and non–Q-
ave myocardial infarction, than on acute or subacute stent
hrombosis. Another small study, based on 60 consecutive
atients with ST-segment elevation myocardial infarction
ho underwent angioplasty and stenting, showed that those
atients in the lowest quartile in terms of responsiveness to
lopidogrel were at an increased risk for a recurrent cardio-
ascular event during a 6-month follow-up (8).
Similarly, in a prospective study of 105 patients under-
oing percutaneous coronary stenting, Muller et al. (28)
ound that the 2 patients who developed stent thrombosis
ere nonresponders to clopidogrel. The Platelet Reactivity
n Patients and Recurrent Events Post-Stenting study,
ased on a sample of 192 patients, showed that post-
reatment ADP-induced aggregation in patients with ad-
erse events was higher as compared with patients without
vents. Also this study did not explore specifically the issue
f DES thrombosis, and did not stratify patients before
linical events to different degrees of platelet reactivity (10).
The strong predictive value of stent thrombosis provided
y a single platelet aggregation assessment, as revealed by
ur study, has important clinical implications since a unique
edside examination may have an impact on revasculariza-ion strategies in the DES era. Alternative revascularization
trategies (coronary surgery or bare-metal stents), or phar-
acologic strategies with the aim of a more complete P2Y12
eceptor inhibition using increasing doses of clopidogrel or
ther antiplatelet agents should be considered to reduce the
isk of ischemic events (29,30).
tudy limitations. Our study is a a clinical trial whose
rimary end point is definite or probable stent thrombosis.
robable stent thrombosis is a clinical end point and may
verestimate the true incidence of stent thrombosis. Con-
ersely, definite stent thrombosis is an angiographic or
athological end point that surely underestimates the true
ncidence of stent thrombosis. However, we tried to over-
ome the intrinsic limitation in probable stent thrombosis
efinition assessing also the cardiac mortality not attribut-
ble to stent thrombosis. We did not report the relation
etween responsiveness to aspirin associated or unassociated
ith nonresponsiveness to clopidogrel that could be a
ariable related to definite or probable stent thrombosis.
eprint requests and correspondence: Dr. David Antoniucci,
ivision of Cardiology, Careggi Hospital, Viale Pieraccini,
-50134, Florence, Italy. E-mail: david.antoniucci@virgilio.it.
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